Skip to main content
Download PDF

Validation of a rapid collagenase activity detection technique based on fluorescent quenched gelatin with synovial fluid samples

BMC Biotechnology volume 24, Article number: 50 (2024) Cite this article

Abstract

Background

Measuring collagenase activity is crucial in the field of joint health and disease management. Collagenases, enzymes responsible for collagen degradation, play a vital role in maintaining the balance between collagen synthesis and breakdown in joints. Dysregulation of collagenase activity leads to joint tissue degradation and diseases such as rheumatoid arthritis and osteoarthritis. The development of methods to measure collagenase activity is essential for diagnosis, disease severity assessment, treatment monitoring, and identification of therapeutic targets.

Results

This study aimed to validate a rapid collagenase activity detection technique using synovial fluid samples. Antibody microarray analysis was initially performed to quantify the levels of matrix metalloproteinase-9 (MMP-9), a major collagenase in joints. Subsequently, the developed gelatin-based test utilizing fluorescence measurement was used to determine collagenase activity. There was a significant correlation between the presence of MMP-9 and collagenase activity. In addition, Lower Limit of Detection and Upper Limit of Detection can be preliminary estimated as 8 ng/mL and 48 ng/mL respectively.

Conclusions

The developed technique offers a potential point-of-care assessment of collagenase activity, providing real-time information for clinicians and researchers. By accurately quantifying collagenase activity, healthcare professionals can optimize patient care, improve treatment outcomes, and contribute to the understanding and management of joint-related disorders. Further research and validation are necessary to establish the full potential of this rapid collagenase activity detection method in clinical practice.

Peer Review reports

Background

Measuring collagenase activity is of utmost importance in the field of joint health and disease management. Collagenases, a group of enzymes responsible for the degradation of collagen, play a critical role in maintaining the balance between collagen synthesis and breakdown within connective tissues within the joint [1, 2]. If the homeostasis controlled by collagenases is disrupted, joint tissue degradation is provoked, causing joint diseases such as rheumatoid arthritis (RA) or osteoarthritis (OA) [3,4,5]. This imbalance results in the progressive erosion of articular cartilage and structural alterations.

Collagenases belong to the matrix metalloproteinase (MMP) family of proteins. The MMP family consists of various enzymes that are involved in the degradation and remodeling of the extracellular matrix (ECM), including collagen. Collagenases, including MMP-1, MMP-8, and MMP-13, primarily cleave collagen fibrils. Gelatinases, represented by MMP-2 and MMP-9, target denatured collagen (gelatin) as well as other ECM constituents. Stromelysins, such as MMP-3, MMP-10, and MMP-11, are involved in the cleavage of various ECM proteins, including proteoglycans and fibronectin. Membrane-type MMPs, exemplified by MT1-MMP, participate in the activation of proMMP-2 and proMMP-13. This orchestrated enzymatic activity is crucial for tissue development, repair, and homeostasis. However, dysregulation of MMPs is associated with pathological conditions such as cancer, arthritis, and cardiovascular diseases.

Therefore, understanding the specific targets of each MMP is essential for therapeutic strategies aimed at modulating ECM remodeling and preventing aberrant tissue changes. Among them, matrix metalloproteinase 9 (MMP-9), also known as gelatinase B, plays a significant role in various physiological and pathological processes in joints. MMP-9 is primarily involved in the breakdown of fibrillar collagens, particularly type IV and V collagens, which are components of the ECM in joint tissues. It cleaves collagen molecules at specific sites, resulting in the fragmentation and degradation of collagen fibers. During inflammatory processes, such as those of RA or OA, MMP-9 is upregulated as part of the innate immune response. It not only contributes to collagen degradation but also promotes the migration of immune cells to the site of inflammation and facilitates the release of cytokines and chemokines, amplifying the inflammatory cascade [6, 7].

In general, collagenases, including matrix metalloproteinase-1 (MMP-1), MMP-8, MMP-9, and MMP-13, play a crucial role in the molecular basis of both RA and OA [8]. These collagenases contribute to the degradation of collagen within the joint, particularly collagen type II, which is a major component of articular cartilage. Increased levels and activity of MMP-1, MMP-8, MMP-9, and MMP-13 in SF are associated with ongoing joint tissue degradation and can serve as diagnostic biomarkers for both RA and OA [9, 10].

MMP-1 primarily digests collagen type I, which is abundant in connective tissues, and III [11, 12]. MMP-8 targets collagen types I [13, 14], while MMP-9 is involved in the breakdown of collagen type IV, the main component of the basement membrane, and gelatin, a form of hydrolyzed collagen [15,16,17]. MMP-13 specifically degrades collagen type II, the primary component of cartilage (Table 1) [18, 19].

Table 1 Summary table of the most important types of MMPs in RA and OA, their names, and the types of collagens they digest
Full size table

In this context, collagenases have emerged as potential therapeutic targets for the treatment of joint diseases. Modulating collagenase activity can help regulate collagen degradation, maintaining the balance between collagen turnover and tissue preservation. Researchers are exploring strategies to selectively inhibit or modulate collagenase activity, aiming to slow joint tissue degradation and potentially delay the progression of joint diseases [9, 10].

In particular, MMPs play a significant role in the homeostasis of synovial fluid (SF), particularly in the context of joint health and disease [20]. In the synovial joints, MMPs are involved in the dynamic turnover and remodeling of the ECM within the SF, a specialized lubricating fluid that surrounds and nourishes the joints [20]. These enzymes contribute to the degradation of collagen, gelatin, and proteoglycans within the SF, influencing the viscosity and composition of this fluid. They are produced by synovial cells and chondrocytes, degrade various ECM molecules (Table 1) maintaining the fluidity and functionality of the synovial fluid, ensuring proper joint lubrication and shock absorption [21,22,23,24,25]. MMPs are also influenced by Calcium, Ca2 + ions are crucial for the catalytic domains of MMPs, playing a vital role in the proper folding of the molecule necessary for substrate recognition and catalysis [26]. Furthermore, this element influences the activity of MMPs through various mechanisms, including binding to calmodulin, modulating integrin-mediated signaling, and participating in intracellular cascades like PKC activation [27]. It also impacts MMP gene expression by regulating transcription factors such as NFAT and AP-1 [28]. In addition, MMPs are tightly regulated by tissue inhibitors of metalloproteinases (TIMPs), balancing ECM synthesis and degradation. This balance facilitates the removal of damaged matrix components and supports the synthesis of new ones, thereby contributing to joint health and the prevention of diseases such as osteoarthritis [29, 30]. Under normal physiological conditions, MMPs help maintain the delicate balance between ECM synthesis and degradation, ensuring proper joint function. However, in conditions such as RA and OA, there is often an imbalance in MMP activity, leading to excessive degradation of the ECM in the SF. This dysregulation contributes to joint damage, inflammation, and the progression of joint diseases. Understanding the intricate interplay between MMPs and SF dynamics is crucial [30, 31].

Therefore, measuring collagenase activity plays a crucial role in diagnosing joint diseases, assessing disease severity, monitoring treatment response, and identifying therapeutic targets [32,33,34]. These measurements provide valuable information for clinicians, researchers, and drug developers, ultimately contributing to the understanding and management of joint-related disorders [32,33,34]. By accurately quantifying collagenase activity, health care professionals can optimize patient care, improve treatment outcomes, and strive to preserve joint health and functionality. The development of a rapid test to assess collagenase activity in SF holds significant importance in the field of joint health and disease management. Currently, the measurement of collagenase activity often involves complex laboratory techniques that require specialized equipment and time-consuming procedures. Among these, widely used tests include zymography, which visually assesses enzyme activity through gel electrophoresis, and fluorogenic assays, which quantitatively measure collagenase activity using specific substrates [35, 36]. Among these substrates, DQ-gelatin, FRET-based peptides, or fluorogenic peptides derived from collagen sequences, such as those containing MCA (7-methoxycoumarin-4-acetyl) and DNP (dinitrophenyl) groups, have been widely used in the study of collagenase activity as they release a fluorescent signal upon cleavage by the enzyme, allowing for real-time and quantitative measurement of enzyme activity [37,38,39,40,41,42]. Immunoassays, such as ELISAs, which detect collagenase antigens, also play a crucial role in providing quantitative insights [43]. These diagnostic tools are invaluable in diagnosing and monitoring conditions associated with collagen degradation, aiding clinicians in making informed decisions about patient management. However, a rapid test could revolutionize the diagnostic process by providing real-time, point-of-care (PoC) assessment of collagenase activity, offering numerous advantages and potential applications.

This work aimed to validate a developed rapid collagenase activity detection technique. This test is based on immobilizing fluorescent quenched gelatin (Gel-FITC) at the bottom of the wells of a microplate. When incubated with synovial fluid, the collagenases in the fluid digest the gelatin, liberating the fluorophore and increasing the fluorescent signal, which, when measured together with a calibration curve, allows the quantification of the collagenase activity of the sample normalized by the presence of the enzyme. We validated this test by comparing the collagenase activity of 22 samples with the presence of MMP-9 previously calculated with antibody microarrays (AbMAs).

The novelty of this research lies in the innovative utilization of fluorescent quenched gelatin as a substrate for collagenase detection. By immobilizing this gelatin at the bottom of microplate wells, a platform that allows for efficient and rapid assessment of collagenase activity has been created. The principle behind this technique, wherein collagenases present in synovial fluid digest the gelatin substrate, liberating a fluorophore and resulting in an increase in fluorescent signal, showcases a useful integration of molecular biology and spectroscopic methods, which offers to researchers and clinicians a valuable tool for studying enzyme kinetics and diagnosing conditions associated with collagen degradation.

The novel Gel-FITC degradation assay, which takes about 30 min, is significantly faster and requires fewer resources compared to traditional methods like zymography, fluorogenic assays, and ELISAs, which take several hours to a full day. This makes the Gel-FITC test an efficient and accessible option for real-time, point-of-care collagenase activity assessment. We selected Gel-FITC for its accessibility, ease of manufacturing, affordability, and stability, making it a practical choice for widespread use in real-time collagenase activity assessment, especially in resource-limited settings. Its simplicity and low cost align with the need for efficient diagnostic tools that can be readily deployed in various healthcare settings.

While the utilization of fluorescent quenched gelatin for collagenase detection presents promising advantages, it is also crucial to acknowledge its potential drawbacks and limitations. It should be noted that the technique’s sensitivity may vary depending on several factors, including the concentration of collagenases in the sample and the efficiency of the gelatin substrate immobilization. In addition, there is a potential batch-to-batch variation in the gelatin substrate, which might affect assay performance and result interpretation. In order to solve all this disadvantages, when verifying, validating and upscaling the manufacturing, effective quality control measures and standardized protocols would be necessary to ensure assay consistency. Furthermore, the need for specialized equipment, such as microplate readers capable of detecting fluorescence, could limit the accessibility of the technique, particularly in resource-limited settings or smaller research laboratories.

Despite these drawbacks, the innovative nature of the technique and its potential applications in enzyme kinetics and disease diagnosis warrant further investigation and optimization to maximize its utility and address existing limitations. Continued refinement and validation efforts will be essential to enhance the reliability and robustness of this collagenase detection method.

Methods

Synovial fluid samples

We designed a validation study in which 22 samples were analyzed. SF samples were obtained from patients who presented with joint effusion due to degenerative knee pathologies. This effusion is extracted in routine medical practice prior to the administration of intra-articular treatments. The samples were aliquoted in 0.5 mL Eppendorf tubes (#40420050, Hamburg, Germany) and stored at − 80 °C until analysis. The collection and processing of samples was carried out by medically qualified personnel after approval from the institutional review board and in strict accordance with the tenets of the Helsinki Declaration regarding research in humans. The corresponding ethical approval was obtained (Protocol No. EPA2015046) from the Ethics Committee of the Basque Country (September 2015). Informed consent was obtained from all the participants after the nature and possible consequences of the study were explained to them.

Antibody microarray analysis of the samples

Based on our previous research with AbMAs [44,45,46,47,48,49], we analyzed the presence of the MMP-9 biomarker in the SF samples. The use of AbMAs was first validated by comparing MMP-9 biomarker quantification using an AbMA and ELISA [47]. The microarrays were fabricated on glass 76 × 26 mm microscope slides with 45° frosted ends (#1053057, LineaLAB, Badalona, Spain) preactivated with acid treatment involving different washing steps to make the surface hydrophobic (EP2048534A4, IMG Pharma Biotech S.L., Zamudio, Spain). Twenty-four AbMAs were printed onto each slide in a four-column, six-row format (Fig. 1). Each AbMA had two replicate spots of rabbit IgG anti-human MMP-9 (#10327-R043, Sino Biological, Beijing, China) immobilized at 200 μg/mL onto SIVG printing solution at 0.05% (IMG Pharma Biotech S.L., Zamudio, Spain). One drop of 30 nL was printed for each spot using a noncontact microarrayer Nano_plotter (NP 2.1., GeSiM mbH, Radeberg, Germany). The AbMAs were printed on each slide under controlled humidity (60%) at room temperature (RT) and stored at − 20 °C until use. Four slides of 24 AbMAs were immobilized on each batch. Four batch printings were carried out.

Fig. 1
figure 1

Schematic representation of a glass slide with printed AbMAs. Twenty-four AbMAs with two spots of rabbit IgG anti-human MMP-9 at 200 μg/mL in 0.05% SIVG were immobilized onto treated slides. Image created with BioRender.com

Full size image

The immunodetection protocol involved first thawing and drying the slides for 30 min at RT in a drying chamber, after which they were then washed three times for 5 min with phosphate-buffered saline containing 0.01% Tween-20 (0.01% PBS-T) with agitation. The AbMAs were left in blocking solution (2.5% milk powder in 0.01% PBS-T) for 10 min at RT and then washed with distilled water. The AbMAs were then incubated overnight at 4 °C in a humid chamber with the samples diluted 1:10 in 0.5% PBS-T and 0.01% sodium dodecyl sulfate (SDS: #436143, Sigma, St. Louis, MA, USA). Alternatively, the slides were probed with the biomarker standard (MMP-9, #10327-HNAH, Sino Biological, Beijing, China) at the desired concentrations to establish calibration curves (Fig. 2).

Fig. 2
figure 2

Schematic diagram of standard curve generation. Serial dilutions are made starting from a stock aliquot of 500 ng/mL of MMP-9. The volumes marked over the arrow are taken from the previous dilution and pipetted onto the previously prepared volumes marked on the bottom of the eppendorf. The final MMP-9 concentrations are indicated at the bottom of the figure

Full size image

A final volume of 20 μL was used for each AbMA. After probing, the slides were washed twice with 0.5% PBS-T and once with 0.01% PBS-T for 10 min each with agitation. The AbMAs were probed for 1 h at RT in a humid chamber with primary rabbit IgG antisera against human MMP-9 (10 μg/mL, diluted in blocking solution). After incubation, the slides were washed once with 0.5% PBS-T and twice with 0.01% PBS-T for 5 min each with agitation. The slides were incubated for 1 h at RT in a humid chamber with an Alexa Fluor 647-conjugated secondary goat anti-rabbit IgG antibody (#ab150079: Abcam, Cambridge, UK) diluted 5 μg/mL in blocking solution. Subsequently, the slides were washed with agitation for 5 min each with 0.5% PBS-T, twice with 0.01% PBS-T, once with PBS, and once with distilled water. The slides were then dried, and the fluorescent signal intensity of the spots was measured at 633 nm in an Agilent G2565BA Microarray Scanner (Agilent Technologies, Santa Clara, CA, USA). The protein concentration was determined based on the standard curve intensities. The protein concentration was determined based on the established calibration curves and using ImageLab software (Bio-Rad, Hercules, CA, USA).

Collagenase activity of the samples

To develop a method to measure collagenase activity in human samples, gelatin-fluorescein (Gel-FITC) conjugate (#M1303, BioVision, Milpitas, CA, USA) was chosen as a substrate for the detection of gelatinases/collagenases and other gelatin-degrading enzymes. This gelatin contains the fluorophore FITC, which is quenched until the gelatin is digested when the fluorophore is released. We used P386 well microplates from Greiner (#781289, Greiner, Madrid, Spain) for the immobilization of the gelatin following the protocol detailed below.

First, Gel-FITC was dissolved in 200 μL of distilled water, resulting in a 5 mg/mL solution, which was kept in a rotary mixer for 30 min. Then, the solution was frozen at -20 °C in 25 aliquots of 5 μL. Before use, the 5 mg/mL Gel-FITC solution was thawed at RT and diluted to a final concentration of 19 μg/mL in 0.1 M PB, pH 7.6. The solution was mixed in a rotary mixer protected from light for 30 min. Next, 50 μL of the solution was pipetted into each of the wells of the P386 microplate, and the plate was dried overnight in an oven at 40 °C for the immobilization of the Gel-FITC. Before incubation, 100 μL of enzyme incubation buffer (50 mM Tris HCl, 150 mM NaCl, 5 mM CaCl2, and 0.01% Tween, pH 7.6) was pipetted into each well of the plate for washing, the plate was incubated for 5 min in an orbital shaker, and the plate was inverted to empty the wells until the incubation buffer was removed. Finally, the samples were incubated 1:1 in enzyme incubation buffer at a final volume of 50 μL per well. Alternatively, the wells were probed with the collagenase standard (MMP-9, #10327-HNAH, Sino Biological, Beijing, China) at the desired concentrations in incubation buffer to establish calibration curves (Fig. 2). The fluorescent signal was read at 485/540 nm at 37 °C for 20 min with lectures every 2 min using a Thermo Scientific Fluoroskan Ascent FL (#1506450, Thermo Fisher Scientific, Waltham, MA, USA). A schematic representation of how this test was performed is presented in Fig. 3.

Fig. 3
figure 3

A brief summary of the protocol for the detection of the collagenase activity of the samples using quenched Gel-FITC. (A) Gel-FITC was added to the bottom of the wells containing P386. The samples were then loaded into each of these wells, whereby collagenases such as MMP-9 digest the gelatin, releasing the fluorophore and increasing the fluorescent signal. (B) The increase in the fluorescence signal over time for each collagenase standard concentration allowed the determination of the relationship between the gelatin digestion rate (RFU/min) and the presence of collagenase (ng/mL)

Full size image

Statistical analysis

Simple bivariate correlation was calculated when comparing Gel-FITC digestion measurements and AbMA quantifications, setting the significance at α = 0.05 using a two-tailed test for validating the reliability of the test. The data were processed with GraphPad Prism 9.2.0 (GraphPad Software, San Diego, CA, USA). Statistical analyses were carried out with SPSS 23.0 software (IBM, Armonk, NY, USA).

Results

Analysis of the MPP-9 concentration in synovial fluid samples by antibody microarrays

The biomarker MMP-9 was analyzed in 22 synovial liquid samples using AbMAs. The concentration of each biomarker was assessed (Fig. 4), and the mean, median, maximum and minimum values were calculated (Table 2). The MMP-9 concentration was determined with AbMAs according to specific protocols. The mean concentration of MMP-9 calculated was 12.42 ng/mL, with a standard error (SEM) of 1.08 ng/mL. The median value was 11.08 ng/mL. The maximum concentration observed in the dataset was 21.89 ng/mL, and the minimum concentration was 3.78 ng/mL.

Fig. 4
figure 4

Column chart plotting the concentration of MMP-9 (ng/mL) calculated with AbMAs for each of the SF samples

Full size image
Table 2 The means, medians, maximum values, and minimum values of the presence of MMP-9 quantified by AbMAs in the 22 SF samples
Full size table

Determination of collagenase activity in synovial fluid samples

The collagenase activity of 22 synovial liquid samples was calculated by Gel-FITC digestion. The activity of collagenases normalized by enzyme presence was assessed (Fig. 5), and the mean, median, maximum and minimum values were calculated (Table 3). Collagenase presence was calculated by Gel-FITC digestion, obtaining a mean value of 26.45 ng/mL, with a standard SEM of 3.26 ng/mL. The median value was 26.85 ng/mL. The maximum concentration observed in the dataset was 48.75 ng/mL, and the minimum concentration was 0.00 ng/mL. In addition, Lower Limit of Detection (LLoD) can be preliminarily estimated as 8 ng/mL as is the lowest collagenase concentration detected when analyzing synovial liquid clinical samples with the developed activity assay. In the same way, Upper Limit of Detection can be preliminarily estimated as 48 ng/mL (Fig. 5).

Fig. 5
figure 5

Column chart plotting the activity of collagenases normalized by enzyme presence (ng/mL) quantified by Gel-FITC digestion in the 22 SF samples under study. Samples 6, 9 and 13 showed no collagenase activity signal. LLoD can be stablished at 8 ng/mL and ULoD can be stablished at 48 ng/mL

Full size image
Table 3 The mean, median, maximum value, and minimum value of the activity of collagenases normalized by enzyme presence (ng/mL) quantified by Gel-FITC digestion in the 22 SF samples
Full size table

Comparison between MMP-9 concentration and collagenase activity

To assess the reliability of this technique, the normalized collagenase activity values obtained were compared with the concentrations of MMP-9 collagenase determined by AbMAs in the same samples. When comparing both values, similar results were obtained (Fig. 6). Additionally, a simple bivariate correlation was calculated, setting the significance at α = 0.05 using a two-tailed test. A Pearson correlation coefficient (r) of 0.5459 was obtained with a significance of (*), and the p value was 0.0156 (p value < 0.05).

Fig. 6
figure 6

Correlation between the concentration of collagenases (ng/mL) calculated by Gel-FITC digestion using the normalized collagenase activity using an MMP-9 reference and the concentration of MMP-9 calculated with AbMAs (ng/mL)

Full size image

Discussion

We developed a rapid test for immobilizing Gel-FITC at the bottom of the wells of a microplate and established a detection protocol for the quantification of collagenase activity in SF. The purpose of this test is the rapid quantification of collagenase activity as an instrument for evaluating joint diseases.

As introduced in the Background section, Gel-FITC is highly suitable due to its ease of accessibility, manufacturability, affordability, and stability. It has been used successfully in different works [50, 51]. Other substrates that can be used instead include fluorescently labeled peptides or proteins [37,38,39,40,41,42]. However, these alternatives might not have been widely adopted due to factors such as higher costs, limited availability, or lesser stability compared to Gel-FITC. Additionally, Gel-FITC’s simplicity and effectiveness make it a preferred choice for many applications.

Our results validated the developed test by comparing the normalized collagenase activity calculated by Gel-FITC digestion with the MMP-9 concentration calculated by using AbMAs. For this purpose, 22 synovial liquid samples were collected and processed using both techniques. After quantification, the observed ranges of enzyme expression and collagenase activity obtained with AbMAs and Gel-FITC, respectively, were within the ranges described in the literature, which are between 0 and 30 ng/mL [20, 50, 51]. It should be noted that the normalized collagenase activity values were greater than the MMP-9 values quantified by AbMAs. This is because not only MMP-9 but also multiple MMPs have collagenolytic activity. Other specific collagenases within the MMP family are known as MMP-1, MMP-8, and MMP-13. These collagenases, which are present in SF, are characterized by their ability to cleave and degrade fibrillar collagens, particularly type I, II, and III collagens, which are abundant in connective tissues, including those found in joints [6].

To validate the Gel-FITC degradation test, a correlation between the collagenase activity calculated by Gel-FITC digestion and the presence of MMP-9 calculated with AbMAs was performed. A statistically significant correlation in the obtained values was observed, indicating that the developed test is a useful and reliable tool for quantifying collagenase activity in human synovial liquid samples.

Collagenase activity measurements can aid in the diagnosis of joint diseases, particularly those characterized by collagen degradation, such as RA and OA. Elevated collagenase activity in the SF may indicate an imbalance in collagen turnover and degradation, indicating ongoing tissue destruction and inflammation [52,53,54]. Moreover, measuring collagenase activity in SF can also help differentiate between different types of arthritis. RA, for instance, is characterized by excessive synovial inflammation and upregulation of collagenase activity [55]. On the other hand, OA, a degenerative joint disease, typically exhibits lower levels of collagenase activity [34]. These distinctions can assist in accurately diagnosing and classifying specific arthritic conditions, leading to more targeted and effective therapeutic approaches. In addition, measuring collagenase activity provides insights into the extent and severity of collagen degradation within the joint [56]. Quantifying collagenase activity levels can help gauge the magnitude of tissue destruction, allowing healthcare professionals to assess disease severity and monitor disease progression over time. Higher levels of collagenase activity may indicate a more aggressive disease course and predict a poorer prognosis [57, 58]. This information can guide treatment decisions and provide prognostic indicators for patients, assisting in determining the appropriate course of action and potential interventions. Furthermore, by periodically measuring collagenase activity, healthcare providers can evaluate the effectiveness of treatments aimed at reducing joint inflammation and preventing collagen degradation. Tracking changes in collagenase activity over time provides valuable feedback on the impact of interventions, allowing for treatment adjustments and optimization of patient care [59].

With these types of collagenase activity tests, researchers can investigate the impact of various factors, such as inflammation or oxidative stress, on collagenase activity levels, providing insights into the underlying pathophysiology of joint diseases [60,61,62]. Moreover, these findings can guide the development of novel therapeutic interventions targeting collagenase or its regulatory mechanisms, potentially leading to the discovery of more effective treatments [63].

One of the strengths of the test developed is its speed and simplicity, which allows it to position itself as a valuable PoC. Detecting elevated collagenase activity levels in SF at an early stage may indicate ongoing joint tissue degradation before clinical symptoms become apparent. This early intervention can lead to more effective treatment strategies, helping to prevent further joint damage and improve long-term prognosis [64,65,66].

However, further research and validation are necessary to establish the full potential of this rapid collagenase activity detection method in clinical practice. To date, collagenase activity measurements should be interpreted in conjunction with other clinical parameters and imaging studies to form a comprehensive diagnostic picture. Combining collagenase activity analysis with imaging techniques such as magnetic resonance imaging (MRI) or ultrasound can provide a more complete assessment of joint health, aiding in accurate diagnosis and treatment planning [67,68,69].

With the aim of summarizing the main advantages of the developed Gel-FITC collagenase activity assay in comparison to current techniques with the same intended use, the following table (Table 4) has been constructed.

Table 4 Comparison between developed Gel-FITC collagenase activity assay and current techniques with the same intended use
Full size table

In summary, the development of a rapid test to assess collagenase activity in SF holds immense importance in joint health. It can enable early diagnosis, aid in treatment monitoring, facilitate personalized care, identify therapeutic targets, and advance research in the field. By providing quick and reliable results, a rapid collagenase activity test has the potential to revolutionize the diagnosis and management of joint diseases, leading to improved patient outcomes and enhanced quality of life. In order to market current Gel-FITC collagenase assay, full package of characterization studies will be performed following CLSI guidelines to determine: Linearity (EP06-A), Detection Capability (EP17-A2), Precision (EP05-A3), Interfering substances (EP07-A3), Method Comparison (EP09-A3/EP12-A2), Bias (EP10-A3), and Stability (EP25-A) [77].

Conclusion

A rapid Gel-FITC degradation test was developed for synovial liquid collagenase activity quantification in human samples. The test was validated through comparison with AbMAs. With the obtained data, we confirmed the reliability of our Gel-FITC test for the quantification of collagenase activity in human synovial liquid samples. The measurement of this parameter offers a valuable diagnostic tool for assessing joint health and detecting various arthritic conditions. By providing insights into collagen turnover and tissue destruction, these measurements can assist in early diagnosis, differentiation between different types of arthritis, and monitoring treatment response. As research continues to unveil the intricacies of collagenase activity, it holds immense potential to revolutionize the diagnosis and management of joint-related disorders, leading to improved patient outcomes and enhanced quality of life.

Data availability

No datasets were generated or analysed during the current study.

References

  1. Holmbeck K, Birkedal-Hansen H. Collagenases. Encyclopedia Biol Chemistry: Second Ed. 2013;542–4. https://doi.org/10.1016/B978-0-12-378630-2.00008-6

  2. Abe S, Shinmei M, Nagai Y. Synovial collagenase and joint diseases: the significancy of latent collagenase with special reference to rheumatoid arthritis. J Biochem. 1973;73:1007–11. https://doi.org/10.1093/OXFORDJOURNALS.JBCHEM.A130154

    Article  CAS  PubMed  Google Scholar 

  3. Pelletier J-P, Martel‐Pelletier J, Howell DS, Ghandur‐Mnaymneh L, Enis JE, Frederick Woessner J. Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis Rheum. 1983;26:63–8. https://doi.org/10.1002/ART.1780260110

    Article  CAS  PubMed  Google Scholar 

  4. Harris ED, Cohen GL, Krane SM. Synovial collagenase: its presence in culture from joint disease of diverse etiology. Arthritis Rheum. 1969;12:92–102. https://doi.org/10.1002/ART.1780120206

    Article  PubMed  Google Scholar 

  5. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. 2002;4:157–64. https://doi.org/10.1186/AR401/FIGURES/2

    Article  CAS  PubMed  Google Scholar 

  6. Löffek S, Schilling O, Franzke CW. Biological role of matrix metalloproteinases: a critical balance. Eur Respir J. 2011;38:191–208. https://doi.org/10.1183/09031936.00146510

    Article  CAS  PubMed  Google Scholar 

  7. Kim KS, Choi HM, Lee YA, Choi IA, Lee SH, Hong SJ, Yang HI, Yoo MC. Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int. 2011;31:543–7. https://doi.org/10.1007/S00296-010-1592-1

    Article  CAS  PubMed  Google Scholar 

  8. Yamamoto K, Wilkinson D, Bou-Gharios G. Targeting dysregulation of metalloproteinase activity in osteoarthritis. Calcif Tissue Int. 2021;109:277. https://doi.org/10.1007/S00223-020-00739-7

    Article  CAS  PubMed  Google Scholar 

  9. Karila T, Tervahartiala T, Cohen B, Sorsa T. The collagenases: are they tractable targets for preventing cartilage destruction in osteoarthritis? https://doi.org/10.1080/14728222. 2022;26:93–105, https://doi.org/10.1080/14728222.2022.2035362

  10. Hu Q, Ecker M. Overview of MMP-13 as a promising target for the treatment of osteoarthritis. Int J Mol Sci. 2021;22:1–22. https://doi.org/10.3390/IJMS22041742

    Article  Google Scholar 

  11. Boraschi-Diaz I, Wang J, Mort JS, Komarova SV. Collagen type I as a ligand for receptor-mediated signaling. Front Phys. 2017;5. https://doi.org/10.3389/FPHY.2017.00012/BIBTEX

  12. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem. 1997;272:2446–51. https://doi.org/10.1074/JBC.272.4.2446

    Article  CAS  PubMed  Google Scholar 

  13. Lu KG, Stultz CM. Insight into the degradation of type-I collagen fibrils by MMP-8. J Mol Biol. 2013;425:1815–25. https://doi.org/10.1016/J.JMB.2013.02.002

    Article  CAS  PubMed  Google Scholar 

  14. Hedenbjörk-Lager A, Hamberg K, Pääkkönen V, Tjäderhane L, Ericson D. Collagen degradation and preservation of MMP-8 activity in human dentine matrix after demineralization. Arch Oral Biol. 2016;68:66–72. https://doi.org/10.1016/J.ARCHORALBIO.2016.04.003

    Article  PubMed  Google Scholar 

  15. Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis. 1999;20:749–55. https://doi.org/10.1093/CARCIN/20.5.749

    Article  CAS  PubMed  Google Scholar 

  16. Heikinheimo K, Salo T. Expression of basement membrane type IV collagen and type IV collagenases (MMP-2 and MMP-9) in human fetal teeth. J Dent Res. 1995;74:1226–34. https://doi.org/10.1177/00220345950740051301

    Article  CAS  PubMed  Google Scholar 

  17. Nyante SJ, Wang T, Tan X, Ozdowski EF, Lawton TJ. Quantitative expression of MMPs 2, 9, 14, and Collagen IV in LCIS and paired normal breast tissue. Scientific Reports. 2019;9:1–9, https://doi.org/10.1038/s41598-019-48602-6

  18. Zhang M, Zhou Q, Liang QQ, Li CG, Holz JD, Tang D, Sheu TJ, Li TF, Shi Q, Wang YJ. IGF-1 regulation of type II collagen and MMP-13 expression in rat endplate chondrocytes via distinct signaling pathways. Osteoarthritis Cartilage. 2009;17:100–6. https://doi.org/10.1016/J.JOCA.2008.05.007

    Article  CAS  PubMed  Google Scholar 

  19. Wang J, Ma J, Gu JH, Wang FY, Shang XS, Tao HR, Wang X. Regulation of type II collagen, matrix metalloproteinase-13 and cell proliferation by interleukin-1β is mediated by curcumin via inhibition of NF-ΚB signaling in rat chondrocytes. Mol Med Rep. 2017;16. https://doi.org/10.3892/MMR.2017.6771

  20. Tchetverikov I, Lohmander LS, Verzijl N, Huizinga TWJ, Tekoppele JM, Hanemaaijer R, Degroot JMMP. Protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. https://doi.org/10.1136/ard.2004.022434

  21. Otero M, Goldring MB. Cells of the synovium in rheumatoid arthritis. Chondrocytes. Arthritis Res Ther. 2007;9:220. https://doi.org/10.1186/AR2292

    Article  PubMed  PubMed Central  Google Scholar 

  22. Önnheim K, Huang S, Strid Holmertz A, Andersson S, Lönnblom E, Jonsson C, Holmdahl R, Gjertsson I. Rheumatoid arthritis chondrocytes produce increased levels of pro-inflammatory proteins. Osteoarthr Cartil Open. 2022;4:100235. https://doi.org/10.1016/J.OCARTO.2022.100235

    Article  PubMed  PubMed Central  Google Scholar 

  23. Akkiraju H, Nohe A. Role of chondrocytes in cartilage formation, progression of osteoarthritis and cartilage regeneration. J Dev Biol. 2015;3:177. https://doi.org/10.3390/JDB3040177

    Article  PubMed  Google Scholar 

  24. Ishikawa S, Hiraizumi Y, Fujimaki E. Production of matrix metalloproteinase (MMP-2, 9) from cultured human synovial cells. Showa Univ J Med Sci. 1999;11:2–7.

    Article  Google Scholar 

  25. Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther. 2006;8:R187. https://doi.org/10.1186/AR2099

    Article  PubMed  PubMed Central  Google Scholar 

  26. Meraz-Cruz N, Ortega A, Estrada-Gutierrez G, Flores A, Espejel A, Hernandez-Guerrero C, Vadillo-Ortega F. Identification of a calcium-dependent matrix metalloproteinase complex in rat chorioallantoid membranes during labour. Mol Hum Reprod. 2006;12:633–41. https://doi.org/10.1093/MOLEHR/GAL072

    Article  CAS  PubMed  Google Scholar 

  27. Tebar F, Lladó A, Enrich C. Role of calmodulin in the modulation of the mapk signalling pathway and the transactivation of epidermal growth factor receptor mediated by PKC. FEBS Lett. 2002;517:206–10. https://doi.org/10.1016/S0014-5793(02)02624-8

    Article  CAS  PubMed  Google Scholar 

  28. Park YJ, Yoo SA, Kim M, Kim WU. The role of calcium–Calcineurin–NFAT signaling pathway in health and autoimmune diseases. Front Immunol. 2020;11:455685. https://doi.org/10.3389/FIMMU.2020.00195/BIBTEX

    Article  Google Scholar 

  29. Plsikova Matejova J, Spakova T, Harvanova D, Lacko M, Filip V, Sepitka R, Mitro I, Rosocha J. A preliminary study of combined detection of COMP, TIMP-1, and MMP-3 in synovial fluid: potential indicators of osteoarthritis progression. Cartilage. 2021;13:S1421–30. https://doi.org/10.1177/1947603520946385

    Article  CAS  Google Scholar 

  30. Fuchs S, Skwara A, Bloch M, Dankbar B. Differential induction and regulation of matrix metalloproteinases in osteoarthritic tissue and fluid synovial fibroblasts. Osteoarthritis Cartilage. 2004;12:409–18. https://doi.org/10.1016/J.JOCA.2004.02.005

    Article  CAS  PubMed  Google Scholar 

  31. Mukherjee A, Das B. The role of inflammatory mediators and matrix metalloproteinases (MMPs) in the progression of osteoarthritis. Biomaterials Biosystems. 2024;13:100090. https://doi.org/10.1016/J.BBIOSY.2024.100090

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Harris ED, Faulkner CS, Brown FE. Collagenolytic systems in rheumatoid arthritis. Clin Orthop Relat Res. 1975;110:303–16. https://doi.org/10.1097/00003086-197507000-00041

    Article  Google Scholar 

  33. Maeda S, Sawai T, Uzuki M, Takahashi Y, Omoto H, Seki M, Sakurai M. Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Ann Rheum Dis. 1995;54:970–5. https://doi.org/10.1136/ARD.54.12.970

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Clark IM, Powell LK, Ramsey S, Hazleman BL, Cawston TE. The measurement of collagenase, tissue inhibitor of metalloproteinases (Timp), and collagenase—timp complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1993;36:372–9. https://doi.org/10.1002/ART.1780360313

    Article  CAS  PubMed  Google Scholar 

  35. Tajhya RB, Patel RS, Beeton C. Detection of matrix metalloproteinases by zymography. Methods Mol Biol. 2017;1579:231. https://doi.org/10.1007/978-1-4939-6863-3_12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Makowski GS, Ramsby ML. Zymographic analysis of latent and activated forms of matrix metalloproteinase-2 and – 9 in synovial fluid: correlation to polymorphonuclear leukocyte infiltration and in response to infection. Clin Chim Acta. 2003;329:77–81. https://doi.org/10.1016/S0009-8981(03)00015-9

    Article  CAS  PubMed  Google Scholar 

  37. Vandooren J, Geurts N, Martens E, Steen PE van den, Jonghe S De, Herdewijn P, Opdenakker G. Gelatin degradation assay reveals MMP-9 inhibitors and function of O-glycosylated domain. World J Biol Chem. 2011;2:14. https://doi.org/10.4331/WJBC.V2.I1.14

    Article  PubMed  PubMed Central  Google Scholar 

  38. Singh N, Bhattacharyya D. Collagenases in an ether extract of bacterial metabolites used as an immunostimulator induces TNF-α and IFN-γ. Int Immunopharmacol. 2014;23:211–21. https://doi.org/10.1016/J.INTIMP.2014.08.026

    Article  CAS  PubMed  Google Scholar 

  39. Fields GB. Using fluorogenic peptide substrates to assay matrix metalloproteinases. Methods Mol Biol. 2001;151:495. https://doi.org/10.1385/1-59259-046-2:495

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Tokmina-Roszyk M, Tokmina-Roszyk D, Bhowmick M, Fields GB. Development of a fluorescence resonance energy transfer assay for monitoring bacterial collagenase triple-helical peptidase activity. Anal Biochem. 2014;453. https://doi.org/10.1016/J.AB.2014.02.024

  41. Liu H, Liang G, Abdel-Halim ES, Zhu JJ. A sensitive and selective quantum dots-based FRET Biosensor for the detection of cancer marker type IV collagenase. Anal Methods. 2011;3:1797–801. https://doi.org/10.1039/C1AY05178D

    Article  CAS  Google Scholar 

  42. Al-Abdullah IH, Bagramyan K, Bilbao S, Qi M, Kalkum M. Fluorogenic peptide substrate for quantification of bacterial enzyme activities. Sci Rep. 2017;7. https://doi.org/10.1038/SREP44321

  43. Yoshioka H, Oyamada I, Usuku G. An assay of collagenase activity using enzyme-linked immunosorbent assay for mammalian collagenase. Anal Biochem. 1987;166:172–7. https://doi.org/10.1016/0003-2697(87)90559-8

    Article  CAS  PubMed  Google Scholar 

  44. Acera A, Rocha G, Vecino E, Lema I, Durán JA. Inflammatory markers in the tears of patients with ocular surface disease. Ophthalmic Res. 2008;40:315–21. https://doi.org/10.1159/000150445

    Article  CAS  PubMed  Google Scholar 

  45. Acera A, Vecino E, Duran JA, Tear. MMP-9 levels as a marker of ocular surface inflammation in conjunctivochalasis. Invest Ophthalmol Vis Sci. 2013;54:8285–91. https://doi.org/10.1167/iovs.13-12235

    Article  CAS  PubMed  Google Scholar 

  46. Acera A, Suárez T, Rodríguez-Agirretxe I, Vecino E, Durán JA. Changes in tear protein profile in patients with conjunctivochalasis. Cornea. 2011;30:42–9. https://doi.org/10.1097/ICO.0B013E3181DEA7D7

    Article  PubMed  Google Scholar 

  47. de la Fuente M, Rodríguez-Agirretxe I, Vecino E, Astigarraga E, Acera A, Barreda-Gómez G. Elevation of tear MMP-9 concentration as a biomarker of inflammation in ocular pathology by antibody microarray immunodetection assays. Int J Mol Sci. 2022;23:5639. https://doi.org/10.3390/ijms23105639

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Joachim SC, Hohberger B, Sanderson J, Unterlauft JD, Wareham LK, Boto De Los Bueis A, De La Fuente M, Montejano-Milner R, Del Hierro Zarzuelo A, Vecino E, et al. A pilot study of a panel of ocular inflammation biomarkers in patients with primary Sj&ouml;Gren&rsquo;s syndrome. Curr Issues Mol Biol. 2023;45:2881–2894. https://doi.org/10.3390/CIMB45040188

  49. Manuel Benitez-Del-Castillo J, Soria J, Acera A, María Muñoz A, Rodríguez S, Suárez T. Quantification of a Panel for Dry-Eye Protein Biomarkers in Tears: A Comparative Pilot Study Using Standard ELISA and Customized Microarrays; 2021.

  50. Stojanovic SK, Stamenkovic BN, Cvetkovic JM, Zivkovic VG, Andjelkovic Apostolovic MR. Matrix metalloproteinase-9 level in synovial fluid-association with joint destruction in early rheumatoid arthritis. 2023. https://doi.org/10.3390/medicina59010167

  51. Tchetverikov I, Ronday HK, Van El B, Kiers GH, Verzijl N, Tekoppele JM, Huizinga TWJ, Degroot J, Hanemaaijer R. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63:881–3. https://doi.org/10.1136/ard.2003.013243

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Lindy S, Turto H, Sorsa T, Halme J, Lauhio A, Suomalainen K, Uitto VJ, Wegelius O. Increased collagenase activity in human rheumatoid meniscus. Scand J Rheumatol. 1986;15:237–42. https://doi.org/10.3109/03009748609092585

    Article  CAS  PubMed  Google Scholar 

  53. Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ. Expression of matrix metalloproteinase 9 (96-Kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum. 1996;39:1576–87. https://doi.org/10.1002/ART.1780390919

    Article  CAS  PubMed  Google Scholar 

  54. Mahmoud RA, EL-Ansary A, El-Eishi HH, Kamal HM, El-Saeed NH. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis. Ital J Biochem. 2005.

  55. Sweeney SE, Firestein GS, Rheumatoid Arthritis. Regulation of synovial inflammation. Int J Biochem Cell Biology. 2004;36:372–8. https://doi.org/10.1016/S1357-2725(03)00259-0

    Article  CAS  Google Scholar 

  56. Hakala M, Risteli L, Manelius J, Nieminen P, Risteli J. Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann Rheum Dis. 1993;52:866–9. https://doi.org/10.1136/ARD.52.12.866

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Kotaniemi A, Isomaki H, Hukala M, Risteli L, Risteli J. Increased type I collagen degradation in early rheumatoid arthritis. J Rheumatol. 1994;21:1593–6.

    CAS  PubMed  Google Scholar 

  58. Aman S, Hakala M, Risteli L, Risteli J, Increased Type I. Collagen degradation is associated with a need for total joint replacement surgery in rheumatoid arthritis. Ann Rheum Dis. 1996;55:147. https://doi.org/10.1136/ARD.55.2.147-A

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Greenwald RA. Monitoring collagen degradation in patients with arthritis. The search for suitable surrogates. Arthritis Rheum. 1996;39:1455–65. https://doi.org/10.1002/ART.1780390904

    Article  CAS  PubMed  Google Scholar 

  60. Fisher GJ, Quan T, Purohit T, Shao Y, Moon KC, He T, Varani J, Kang S, Voorhees JJ. Collagen fragmentation promotes oxidative stress and elevates matrix metalloproteinase-1 in fibroblasts in aged human skin. Am J Pathol. 2009;174:101. https://doi.org/10.2353/AJPATH.2009.080599

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol. 2001;280. https://doi.org/10.1152/AJPCELL.2001.280.1.C53

  62. Schock BC, Sweet DG, Ennis M, Warner JA, Young IS, Halliday HL. Oxidative stress and increased type-IV collagenase levels in bronchoalveolar lavage fluid from newborn babies. Pediatr Res. 2001;50:29–33. https://doi.org/10.1203/00006450-200107000-00008

  63. Alipour H, Raz A, Zakeri S, Dinparast Djadid N. Therapeutic applications of collagenase (metalloproteases): a review. Asian Pac J Trop Biomed. 2016;6:975–81. https://doi.org/10.1016/J.APJTB.2016.07.017

    Article  CAS  Google Scholar 

  64. Chu CR, Williams AA, Coyle CH, Bowers ME. Early diagnosis to enable early treatment of pre-osteoarthritis. Arthritis Res Ther. 2012;14:212. https://doi.org/10.1186/AR3845

    Article  PubMed  PubMed Central  Google Scholar 

  65. Chu CR, Millis MB, Olson SA, Osteoarthritis. From palliation to prevention: AOA critical issues. J Bone Joint Surg Am. 2014;96(1). https://doi.org/10.2106/JBJS.M.01209

  66. Kandahari AM, Yang X, Dighe AS, Pan D, Cui Q. Recognition of immune response for the early diagnosis and treatment of osteoarthritis. J Immunol Res. 2015;2015. https://doi.org/10.1155/2015/192415

  67. Jerban S, Chang EY, Du J. Magnetic resonance imaging (MRI) studies of knee joint under mechanical loading: review. Magn Reson Imaging. 2020;65:27–36. https://doi.org/10.1016/J.MRI.2019.09.007

    Article  PubMed  Google Scholar 

  68. Østergaard M, Boesen M. Imaging in rheumatoid arthritis: the role of magnetic resonance imaging and computed tomography. Radiol Med. 2019;124:1128–41. https://doi.org/10.1007/S11547-019-01014-Y

    Article  PubMed  Google Scholar 

  69. Sudoł-Szopińska I, Jans L, Teh J. Rheumatoid arthritis: what do MRI and ultrasound show. J Ultrason. 2017;17. https://doi.org/10.15557/JOU.2017.0001

  70. Bergmann U, Michaelis J, Oberhoff R, Knäuper V, Beckmann R, Tschesche H. Enzyme linked immunosorbent assays (ELISA) for the quantitative determination of human leukocyte collagenase and gelatinase. J Clin Chem Clin Biochem. 1989;27:351–60. https://doi.org/10.1515/CCLM.1989.27.6.351

    Article  CAS  PubMed  Google Scholar 

  71. Cooper TW, Bauer EA, Eisen AZ. Enzyme-linked immunosorbent assay for human skin collagenase. Coll Relat Res. 1983;3:205–15. https://doi.org/10.1016/S0174-173X(83)80004-1

    Article  CAS  PubMed  Google Scholar 

  72. Balbín M, Fueyo A, Knäuper V, Pendás AM, López JM, Jiménez MG, Murphy G, López-Otín C. Collagenase 2 (MMP-8) expression in murine tissue-remodeling processes. Analysis of its potential role in postpartum involution of the uterus. J Biol Chem. 1998;273:23959–68. https://doi.org/10.1074/JBC.273.37.23959

    Article  PubMed  Google Scholar 

  73. Kassegne K, Hu W, Ojcius DM, Sun D, Ge Y, Zhao J, Yang XF, Li L, Yan J. Identification of collagenase as a critical virulence factor for invasiveness and transmission of pathogenic leptospira species. J Infect Dis. 2014;209:1105–15. https://doi.org/10.1093/INFDIS/JIT659

    Article  CAS  PubMed  Google Scholar 

  74. Ricci S, D’Esposito V, Oriente F, Formisano P, Di Carlo A, Substrate-Zymography. A still worthwhile method for gelatinases analysis in biological samples. Clin Chem Lab Med. 2016;54:1281–90. https://doi.org/10.1515/CCLM-2015-0668

    Article  CAS  PubMed  Google Scholar 

  75. Ren Z, Chen J, Khalil RA. Zymography as a research tool in the study of matrix metalloproteinase inhibitors. Methods Mol Biol. 2017;1626:79. https://doi.org/10.1007/978-1-4939-7111-4_8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Clift CL, Drake RR, Mehta A, Angel PM. Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin embedded tissue sections. Anal Bioanal Chem. 2021;413:2709. https://doi.org/10.1007/S00216-020-03047-Z

    Article  CAS  PubMed  Google Scholar 

  77. Clinical & Laboratory Standards Institute: CLSI Guidelines Available online: https://clsi.org/ (accessed on 12. May 2024).

Download references

Acknowledgements

The authors would like to thank all the members of our teams who helped in completing this work.

Funding

This research was funded by the Basque Government (BIKAINTEK, grant number 48-AF-W2-2019-00006), by the University of the Basque Country (PIFIND19/02, grant number 201900016247), and by ELKARTEK (KK-2019/00086) and MINECO-Retos (PID2019-111139RB-I00) grants to E.V., as well as by FISS-21-RD21/0002/0041 to A.A.

Author information

Authors and Affiliations

  1. Department of Cell Biology and Histology, Experimental Ophthalmo-Biology Group (GOBE, www.ehu.eus/gobe), University of the Basque Country UPV/EHU, Leioa, 48940, Spain

    Miguel de la Fuente, Arantxa Acera & Elena Vecino

  2. Advanced Biological Therapy Unit, Hospital Vithas Vitoria, Vitoria-Gasteiz, 01008, Spain

    Diego Delgado, Maider Beitia & Mikel Sanchez

  3. Research and Development Division, IMG Pharma Biotech, Zamudio, Bizkaia, Spain

    Gabriel Barreda-Gómez

  4. Ikerbasque, Basque Foundation for Science, Bilbao, 48001, Spain

    Arantxa Acera

  5. Arthroscopic Surgery Unit, Hospital Vithas Vitoria, Vitoria-Gasteiz, 01008, Spain

    Mikel Sanchez

Authors
  1. Miguel de la Fuente
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diego Delgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maider Beitia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gabriel Barreda-Gómez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arantxa Acera
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mikel Sanchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Elena Vecino
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization, Elena Vecino, Arantxa Acera, and Gabriel Barreda-Gómez; Data curation, Miguel de la Fuente; Formal analysis, Miguel de la Fuente, Arantxa Acera, and Gabriel Barreda-Gómez; Funding acquisition, Elena Vecino, Arantxa Acera, and Gabriel Barreda-Gómez; Investigation, Miguel de la Fuente; Methodology, Miguel de la Fuente; Project administration, Arantxa Acera, and Gabriel Barreda-Gómez; Resources, Diego Delgado, Mikel Sanchez, Elena Vecino, Arantxa Acera, and Gabriel Barreda-Gómez; Supervision, Arantxa Acera, and Gabriel Barreda-Gómez; Writing—original draft, Miguel de la Fuente; Writing—review and editing, Miguel de la Fuente, Maider Beitia, Diego Delgado, Mikel Sanchez, Elena Vecino, Arantxa Acera, and Gabriel Barreda-Gómez; Supervision, Arantxa Acera, and Gabriel Barreda-Gómez. All the authors have read and approved the final manuscript.

Corresponding author

Correspondence to Elena Vecino.

Ethics declarations

Ethics approval and consent to participate

The study was conducted in accordance with the Helsinki Declaration. Ethical approval for this study (Protocol No. EPA2015046) was obtained from the Ethics Committee of the Basque Country (September 2015), as was written informed consent. Informed consent was obtained from all subjects involved in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de la Fuente, M., Delgado, D., Beitia, M. et al. Validation of a rapid collagenase activity detection technique based on fluorescent quenched gelatin with synovial fluid samples. BMC Biotechnol 24, 50 (2024). https://doi.org/10.1186/s12896-024-00869-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12896-024-00869-y

Keywords

BMC Biotechnology

ISSN: 1472-6750

Contact us